To manage long COVID by selective SARS-CoV-2 infection biosensing  

作　　者：Ajeet Kaushik Ebrahim Mostafavi 

机构地区：[1]NanoBiotech Laboratory,Department of Environmental Engineering,Florida Polytechnic University,Lakeland,FL,USA [2]Stanford Cardiovascular Institute,Stanford University School of Medicine,Stanford,CA 94305,USA [3]Department of Medicine,Stanford University School of Medicine,Stanford,CA 94305,USA

出　　处：《The Innovation》2022年第5期9-10,共2页创新（英文）

基　　金：support from the National Institute of Biomedical Imaging and Bioengineering(5T32EB009035).

摘　　要：According to the National Institutes of Health(NIH),the initiative of The Rapid Acceleration of Diagnostics Tech and Advanced Technology Platforms(RADxTech/ATP)program was established to promote research and development(R&D)in the field of investigating selective,sensitive,and affordable sensing technologies for coronavirus disease 2019(COVID-19)diagnostics.This is a goaloriented approach toward point-of-care testing(POCT)and severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection management applications.Till May 2022,RADxTech/ATP has been involved in 1.9 billion tests production,44 FDA authorized tests,first over-the-counter test for POCT and home-based testing,and>100 companies dedicated to smart sensor development(https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-dashboard).Despite such outstanding growth,COVID-19 management is far from in control due to SARS-CoV-2 mutations,virus presence in life systems(including human-to-human transmission,water,food,animal,and air[mainly indoor premises])。

关 键 词：POCT INFECTION ACUTE 

分 类 号：R373[医药卫生—病原生物学] TP212.3[医药卫生—基础医学]